Earli
Earli Inc. is a biotechnology company based in Redwood City, California, founded in 2018. The company aims to transform cancer treatment by enabling early detection and localized therapy through its innovative synthetic biology platforms. Earli has successfully raised $119.5 million in funding, with a significant $60 million round completed recently. The company specializes in developing programmable genetic constructs that activate specifically in cancer cells. This technology leads to the production of synthetic biomarkers, known as "Synthetic Biopsies," which can be detected through PET imaging. This method enhances the sensitivity of cancer detection, particularly for small or early-stage tumors. Earli's focus is on early cancer detection and localized treatment, with applications across various cancer types, including breast cancer. The company has also secured patents for its synthetic biomarker techniques, reinforcing its commitment to advancing oncology research and diagnostics.
Work at Earli in HR or recruiting? Claim this page
Headcount trend
Earli went from 32 employees in Jul 2023 to 33 in Jun 2025. Jan to Jun 2025: 1 people joined, 1 left.
Headcount data through Jun 2025
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Aug 2024 | Venture | โ | โ | โ |
| Jan 2021 | Series A | $40M | 5 |
Org structure
Headcount by department
H-1B sponsorship
The department split adds up all the years listed above. FY2026 alone: 1 filings.
Peer reviews
Worked with someone at Earli?
Anonymous peer reviews on OffTheRecord
Similar companies
Earli FAQ
How many employees does Earli have?
Earli has about 33 employees, up 3.1% over the 3 months to Jun 2025.
Does Earli sponsor H1B visas?
Yes. Earli filed 1 H1B (LCA) application in FY2026, according to the latest U.S. Department of Labor disclosures. It was for a Engineering role.
How much funding has Earli raised?
Earli has raised $40M in total funding.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.